Tonix Pharmaceuticals Holding Corp. conducted its annual meeting of shareholders on May 8, 2025. Shareholders approved several proposals during the meeting. Eight individuals were elected to the Board of Directors. The amendment to the Company's Amended and Restated Stock 2020 Stock Incentive Plan, increasing the number of shares available for awards, was approved. The 2025 Employee Stock Purchase Plan received approval. The authorization for the Board of Directors to effect one or more reverse stock splits within a specified range was also approved. Additionally, the appointment of EisnerAmper LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025, was ratified.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.